Amgen Inc. reported better-than-expected first-quarter results even as some newer drugs that analysts expect to drive growth over the next few years underperformed.
Amgen (NASDAQ:AMGN) executives said the company delivered a “strong first quarter” and remains positioned to meet its goals ...
The FDA’s real-time clinical trial mechanism allows drug sponsors to transmit data immediately to the regulator through the ...
The biotechnology company reported a profit of $1.82 billion, driven by a 4% rise in product sales.
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to ...
The US Food and Drug Administration (FDA) is launching a pilot to implement real-time clinical trials (RTCT). While ...
Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.
Regeneron Pharmaceuticals Inc. asked a federal judge to require Amgen Inc. to turn over damages evidence for antitrust ...
The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in real time, with ...
Investor's Business Daily on MSN
Amgen's numbers are out: It gets to keep its cholesterol crown — for now
Amgen widely beat the Street's first-quarter expectations late Thursday, slightly ticking its 2026 guidance higher.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results